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Effect of L-NAME, an Inhibitor of Nitric
Oxide Synthesis, on Cardiopulmonary
Function in Human Septic Shock*
Jurgen A.M. Avontuur, MD; Rudolf P. Tutein Nolthenius, MD;
Steven L.C.E. Buijk, MD; Karan J.K. Kanhai, MD; and
Hajo A. Bruining, MD, PhD
Study objectives: We tested the effects of continuous infusion of NG-nitro-L-arginine methyl ester
(L-NAME), an inhibitor of nitric oxide (NO) synthesis, on cardiovascular performance and
pulmonary gas exchange in patients with hyperdynamic septic shock.
Design: Prospective clinical study.
Setting: ICU of a university hospital.
Patients: Eleven critically ill patients with severe refractory septic shock.
Interventions: Standard hemodynamic measurements were made and blood samples taken
before, during, and after 12 h of continuous infusion of 1 mg/kg/h of L-NAME.
Measurements and results: Continuous infusion of L-NAME increased mean arterial pressure
(MAP) from 6563 (SEM) to 9364 mm Hg and systemic vascular resistance (SVR) from 9626121
to 1,5636173 dyne z s z cm25/m2. Parallel to this, cardiac index (CI) decreased from 4.860.4 to
3.960.4 L/min/m2 and myocardial stroke volume (SV) was reduced from 4363 to 3463 mL/m2.
Left ventricular stroke work was increased in the first hour of L-NAME infusion from 3163 to
4364 g z m/m2 (all p<0.01 compared with baseline). Heart rate, cardiac filling pressures, and
right ventricular stroke work did not change significantly (p>0.05). L-NAME increased the ratio
of arterial PO2 to the fraction of inspired O2 from 167623 to 212627 mm Hg (p<0.05). Venous
admixture (QVA/QT) was reduced from 19.462.6% to 14.262.1% (p<0.05) and oxygen extraction
ratio increased from 21.162.4% to 25.362.7% (p<0.05). Oxygen delivery (DO2) was reduced
following L-NAME, whereas oxygen uptake and arterial lactate and pH were unchanged.
Conclusions: Prolonged inhibition of NO synthesis with L-NAME can restore MAP and SVR in
patients with severe septic shock. Myocardial SV and CI decrease, probably as a result of
increased afterload, since heart rate and stroke work were not reduced. L-NAME can improve
pulmonary gas exchange with a concomitant reduction in QVA/QT. L-NAME did not promote
anaerobe metabolism despite a reduction in DO2. (CHEST 1998; 113:1640-46)
Key words: analogues of L-arginine; cardiac performance; inhibitors of nitric oxide synthesis; NG-nitro-L-arginine
methyl ester; nitric oxide; pulmonary gas exchange; sepsis
Abbreviations: CI5cardiac index; Do25oxygen delivery; FIo25fraction of inspired oxygen; L-NAME5N
G-nitro-L-
arginine methyl ester; L-NNA5NG-nitro-L-arginine; LVSW5left ventricular stroke work; MAP5mean systemic arterial
pressure; NO5nitric oxide; P(A-a)O25alveolar-arterial oxygen pressure difference; PAP5pulmonary artery pressure;
PVR5pulmonary vascular resistance; Qva/Qt5venous admixture; RVSW5right ventricular stroke work;
SVR5systemic vascular resistance; SV5stroke volume; V˙o25oxygen uptake
S epsis and septic shock are characterized by mas-sive systemic vasodilatation with low vascular
resistance, increased cardiac output despite myocar-
dial depression, decreased sensitivity to cat-
echolamines, and high mortality rate.1,2 Recent evi-
dence suggests that pathologic overproduction of the
nitric oxide (NO) radical, a potent vasodilator for-
merly known as endothelium derived relaxing factor,
is at least in part responsible for the cardiovascular
dysfunction seen in sepsis and endotoxemia.3,4
Under normal conditions, small amounts of NO are
formed from L-arginine by the constitutive NO syn-
thase present in the vascular endothelium. This results
in a constant vasodilatory tone maintaining adequate
tissue perfusion. Upon stimulation by endotoxins (lipo-
polysaccharides) and cytokines such as tumor necrosis
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factor and interleukin-1, an inducible calcium indepen-
dent isoform of NO synthase is formed in various cell
types. This inducible enzyme differs from the constitu-
tive isoform in that it releases massive amounts of NO
over long periods of time, resulting in profound
vasodilatation, hypotension, and resistance to cat-
echolamines.3 Furthermore, the early hypotension and
hyporeactivity to constrictors seen after exposure to
endotoxins may result from increased activity of the
constitutive enzyme.5 High levels of nitrite and nitrate,
the stable end product of NO metabolism, are found in
patients with severe sepsis, and these levels may corre-
late with vasodilation.6 Recently, NO has been incrim-
inated in cascade leading to the myocardial depression
during sepsis, as suggested by in vitro studies.7,8
Both the constitutive and inducible isoform of NO
synthase are competitively inhibited by NG-substituted
analogues of L-arginine, such as NG-monomethyl-argi-
nine (L-NMMA), NG-nitro-L-arginine (L-NNA), and
NG-nitro-L-arginine methyl ester (L-NAME).9,10 Infu-
sion of these analogues of L-arginine can reverse
endotoxin- or cytokine-induced hypotension and can
restore reactivity to catecholamines in animals.11-13 In
patients with septic shock, short-term administration of
these inhibitors of NO synthesis has been shown to
increase BP and systemic vascular resistance
(SVR).14-16 Furthermore, methylene blue, an inhibitor
of soluble guanylate cyclase that is the effector enzyme
of NO, has been shown to temporarily raise BP in
patients with sepsis.17 Therefore, inhibitors of NO
synthesis have been suggested to be of value in the
treatment of hypotension during human septic shock.
However, little data are present about the effects of
continued inhibition of NO synthesis on cardiovascular
performance in human sepsis, and the effect on pul-
monary function remains to be determined.18 Since
inhalation of NO can improve oxygenation in patients
with ARDS, one could hypothesize that systemic inhi-
bition of NO synthesis could compromise pulmonary
gas exchange through pulmonary vasoconstriction.19
The present study was designed to assess the
effects of prolonged inhibition of NO synthesis on
cardiovascular performance and pulmonary gas ex-
change during continuous infusion of L-NAME for
12 h in patients with severe septic shock. To study
the effect of L-NAME on NO production, measure-
ments were made of serum nitrite and nitrate levels.
Materials and Methods
Subjects
The hospital’s Medical and Ethics Committee approved the
study. First-degree relatives were informed of the nature of the
study and gave informed consent. Eleven adult critically ill
patients of the ICU of our hospital were included in the study.
All patients met the criteria of sepsis as described by Bone et
al.20 These criteria include evidence of infection, tachycardia
(.90 beats/min in the absence of b-adrenergic receptor block-
ade), tachypnea (respiratory rate .20 breaths/min or the require-
ment of mechanical ventilation), fever or hypothermia (temper-
ature .38.3°C or ,35.6°C), plus at least one of the following
signs of inadequate organ perfusion: PaO2/fraction of inspired
oxygen (FIo2) ,280 (without other pulmonary or cardiovascular
disease as the cause), increased blood lactate levels (.2 mmol/L),
and oliguria (,0.5 mL/kg/h) for at least 1 h. All patients were in
shock (systolic BP ,90 mm Hg or a decrease .40 mm Hg from
baseline unresponsive to fluid challenge) at the time of ICU
admission requiring therapy with pressor agents. At the time of
the study, all patients were receiving dopamine .15 mg/kg/min
and/or norepinephrine (Noradrenaline) .0.1 mg/kg/min. All pa-
tients had respiratory failure and required mechanical ventilation.
Patients received antibiotic therapy based on culture results.
Four patients required continuous hemodialysis because of renal
failure. Only patients with cardiac index (CI) .3.0 L/min/m2
were included since earlier reports have shown reductions of
cardiac output during inhibition of NO synthesis.14-16 We hypoth-
esized that a further reduction in cardiac output would be
undesirable and even dangerous in a state where cardiac output
is reduced. Exclusion criteria for the study were severe coronary
artery stenosis (angina pectoris grade III according to New York
Heart Association classification), pregnancy, and CI ,3.0 L/min/
m2.
Study Protocol
All patients underwent continuous ECG monitoring and had
indwelling radial artery and pulmonary artery catheters (Criti-
cath; Ohmeda; Singapore). Mean systemic arterial BP (MAP),
central venous pressure, and mean pulmonary artery pressure
(PAP) were measured continuously. Triplicate measurements of
cardiac output were made according to the thermodilution
method, and the mean value was reported. Data were recorded
on a computerized data system (Mennen Medical Systems;
Clarence, NY). Cardiac output and pulmonary artery occlusion
pressure were measured 3 and 6 h before L-NAME infusion
(T526 and 23 h), at baseline (T50), during L-NAME infusion
(T50.5, 1, 3, 6, and 12 h), and 3 and 6 h following L-NAME
infusion (T515 and 18 h). L-NAME was obtained from the
manufacturer (Sigma Chemical; St. Louis). The hospital phar-
macy prepared a sterile and pyrogen-free solution of L-NAME,
10 mg/mL, ready for infusion. Within 6 h after inclusion, baseline
measurements were made and L-NAME, 1 mg/kg/h, infusion was
started and continued for 12 h. If mean arterial BP increased
.100 mm Hg, the administration of vasopressors was gradually
reduced and the dosage noted. Concomitant therapy was at the
discretion of the clinician treating the patient. Continuous infu-
sion of L-NAME was chosen since the effect of a bolus injection
of 0.15 mg/kg L-NAME lasted only 5 to 10 min (unpublished
observations).
In a prior dose-finding experiment, L-NAME was given as a
continuous infusion at a rate of 1.5 mg/kg/h in two patients with
severe sepsis. This resulted in unacceptable high PAP in both
patients for which L-NAME infusion had to be stopped (unpub-
lished observations). Therefore, in the present study, a lower
dose of L-NAME, 1 mg/kg/h, was chosen that did not result in
pulmonary hypertension. Before and after administration of
L-NAME, blood was withdrawn for routine measurement of
serum electrolytes, creatinine, liver function tests, lactate, hemo-
globin, platelets, and leukocytes. Arterial and central venous
blood was withdrawn at T50, 1, 3, 6, 12, and 15 h and blood
gases, pH, and hemoglobin content were analyzed (ABL505;
Radiometer; Copenhagen) for determination of pulmonary gas
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exchange parameters, oxygen delivery (Do2), and oxygen con-
sumption (V˙o2). Since central venous blood gas measurements
were incomplete in three patients, mean values of gas exchange
parameters and related calculations are reported for only eight
patients. In all patients, blood was withdrawn at T50, 1, 3, 6, 12,
15, 18, and 24 h for determination of nitrite and nitrate levels, the
stable end products of NO metabolism, and analyzed using an
automated procedure based on the Griess reaction.21 Serum from
eight postoperative ICU patients without sepsis or shock served
as control for nitrite and nitrate levels.
Calculations and Statistical Analysis
Calculations were performed according to standard formulas.
Recorded variables were compared with baseline values using
Student’s paired t test with Bonferroni correction. Nitrite/nitrate
levels were compared with control using Student’s unpaired t
test. A p value ,0.05 was considered statistically significant. Data
are expressed as mean6SEM.
Results
Patient characteristics are shown in Table 1. Most
patients had an intra-abdominal infection as the
cause for sepsis. Cultures of the infective focus
revealed both Gram-negative and Gram-positive
bacteria with positive blood cultures in 45% of
patients. Mortality at 28 days was 55% and one
patient died at day 34 when treatment was discon-
tinued because of inoperable surgical problems. No
obvious link was noted between deaths and infusion
of L-NAME.
Continuous infusion of L-NAME resulted in an
increase in BP (MAP), SVR, PAP, and pulmonary
vascular resistance (PVR) that was direct in onset
(Table 2; p,0.01). Parallel to these changes, CI and
myocardial stroke volume (SV) were reduced (Table
2 and Fig 1; p,0.01). Left ventricular stroke work
(LVSW) was increased only in the first hour of
L-NAME infusion whereas right ventricular stroke
work (RVSW) was not significantly changed (Fig 1).
Heart rate and cardiac filling pressures did not
change significantly (Table 2). L-NAME infusion
resulted in improved arterial oxygenation (Fig 2 and
Table 3) with a maximum increase in the ratio of
PaO2/FIo2 from 167623 to 212627 mm Hg after
3 h of L-NAME infusion (p,0.05). Venous admix-
ture (Qva/Qt) was reduced from 19.462.6% to a
minimum of 14.262.1% (p,0.05) after 6 h of L-
NAME infusion (Fig 2) and oxygen extraction ratio
increased from 21.162.4% to 25.362.7% (p,0.05).
No significant changes were seen in partial PaCO2
and alveolar-arterial oxygen pressure difference (Ta-
ble 3). The positive end-expiratory pressure level was
not significantly changed during L-NAME infusion
(5.762.0 vs 4.762.0 cm H2O at the end of L-NAME
infusion, p.0.05). Other ventilatory parameters such
as mean airway pressure, peak inspiratory pressure,
and minute volume were unchanged (not shown).
V˙o2 was unchanged despite a reduction in (Do2)
(Table 3). Vasopressor support was significantly re-
duced during L-NAME administration (dopamine
from 1,9206170 to 1,6306200 mg/min and norepi-
nephrine [Noradrenaline] from 8.362.1 to 7.562.3
mg/min at the end of L-NAME infusion; both
p,0.05). During continuous infusion of L-NAME,
the hemodynamic effects persisted, although the
effects on MAP were most pronounced in the early
stages of L-NAME administration. CI and SV re-
mained depressed throughout the whole 12-h infu-
sion period. At baseline, nitrite/nitrate levels ranged
from 13 to 86 (median, 37) mmol/L in the study
group, which was increased compared with control
(range, 5 to 17 [median, 11] mmol/L; p,0.05).
Serum nitrate and nitrite showed no significant
changes during L-NAME infusion (Fig 3). Urine
output increased from 92627 mL/h to a maximum of
157659 mL/h during L-NAME infusion, which was
not statistically significant (n57; p50.09). Arterial
lactate (from 3.761.2 to 3.060.7 mmol/L) and arte-
rial pH (from 7.3660.02 to 7.3660.02) were not
significantly changed after the 12 h of L-NAME
Table 1—Patient Characteristics*
Characteristics No.
Age, yr 51.763.9
Sex, M/F 10/1
APACHE II score† 20.761.0
Sepsis Severity Score‡ 20.860.9
Source of sepsis
Peritonitis 5
Pneumonia 2
Pancreatitis 2
Mediastinitis 1
Peritonitis1pneumonia 1
Bacteria
Local culture
Enterococcus faecalis 6
Staphylococcus epidermidis 3
Klebsiella pneumoniae 1
Streptococcus pneumoniae 1
Escherichia coli 1
Clostridium difficile 1
Bacteroides species 1
Blood culture
E faecalis 1
Pseudomonas aeruginosa 1
Staphylococcus aureus 1
Proteus vulgaris 1
K pneumoniae 1
Mechanical ventilation 11
PEEP,§ (cm H2O) 5.762.0
Mortality (at day 28) 6/11
*Values are displayed as mean6SEM of 11 patients.
†APACHE II5Acute Physiology and Chronic Health Evaluation,
Knaus et al.22
‡Sepsis Severity Score as described by Elebute and Stoner.23
§PEEP5positive end-expiratory pressure.
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infusion. Also, serum electrolytes, urea, creatinine,
liver function test results, platelets, and leukocytes
were not significantly changed at the end of L-
NAME infusion (results not shown). During admin-
istration of L-NAME, no changes were seen in the
ECG. No side effects were seen during administra-
tion of L-NAME.
Discussion
The mortality rate from septic shock remains high
despite progress in antibiotic and vasopressor ther-
apy, and therefore new treatment modalities are
warranted.1 Increased production of NO by the
Figure 1. Effects of continuous infusion of 1 mg/kg/h of
L-NAME on cardiac performance in 11 patients with severe
septic shock. SW5stroke work. Time of L-NAME infusion is
from t50 to t512 h. Values are displayed as mean6SEM.
Asterisk: p,0.05 for comparison to the baseline value.
Figure 2. Effect of continuous infusion of 1 mg/kg/h of L-
NAME on pulmonary gas exchange in patients with severe septic
shock. PaO2/FIo2, n511; Qva/Qt, n58. Time of L-NAME
infusion is from t50 to t512 h. Values are displayed as
mean6SEM. Asterisk: p,0.05 for comparison to the baseline
value.
Table 2—Effect of L-NAME Infusion on Hemodynamic Variables in Patients With Severe Sepsis*
Continuous L-NAME Infusion, 1 mg/kg/h
Baseline 0.5 h 1 h 3 h 6 h 12 h 15 h 18 h 24 h
CI, L/min/m
2
4.860.4 4.460.4† 4.360.4† 3.960.4† 4.060.4† 4.160.4† 4.260.4† 4.260.3† 4.460.4
MAP, mm Hg 6563 9364† 8764† 8064† 7563† 7163† 6663 6663 6863
SVR, dyne z s z cm25/m2 9626121 1,5636173† 1,5316183† 1,4836172† 1,4106173† 1,2066137† 1,0886127 1,0926124 1,0966131
PAP, mm Hg 3162 3562† 3662† 3662† 3362 3162 3062 3062 3062
PVR, dyne z s z cm25/m2 329631 432651† 463651† 475653† 469657† 418649 380638 376643 374641
HR, beats/min 11264 11064 10864 11264 11064 11064 10765 10865 10865
CVD, mm Hg 12.961.0 14.161.1 13.561.2 14.161.3 11.861.0 11.761.3 11.760.9 11.960.7 11.661.3
PAOP, mm Hg 12.760.9 14.160.9 13.960.9 14.461.2 12.760.9 12.361.1 12.260.8 12.660.8 12.961.0
*HR5heart rate, CVD5central venous pressure; PAOP5pulmonary artery occlusion pressure. Values are displayed as mean6SEM of 11
patients.
†p,0.05 for comparison to the baseline value.
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inducible NO synthase has been implicated as a
major contributor to the cardiovascular dysfunction
of endotoxin- and cytokine-induced shock in ani-
mals.11-13 The present study shows that NO is re-
sponsible, at least in part, for the hemodynamic
derangements in patients with severe sepsis. Pro-
longed inhibition of NO synthesis with L-NAME
could improve cardiovascular status and pulmonary
gas exchange in these severely ill patients and may
provide a new treatment modality in the manage-
ment of septic shock.
Although no conclusions can be made regarding
mortality in this nonrandomized study with only 11
patients, the mortality rate was high (.60%), which
could raise questions regarding the safety of L-
NAME. However, no obvious deterioration of con-
dition was noted during L-NAME infusion and
mortality was not different from predicted death rate
as computed by the APACHE II (acute physiology
and chronic health evaluation) and Sepsis Severity
scores.22,23 Some animal studies have shown detri-
mental effects and increased mortality following
L-NAME and other analogues of L-arginine during
septic shock.24,25 The detrimental effects of these
NO synthase inhibitors have contributed to their
nonspecificity toward the constitutive isoform of NO
synthase, and selective inhibition of the inducible
enzyme has been suggested to be more effective.25,26
Recent reports, however, suggest that the constitu-
tive form of NO synthase disappears in endotoxemia
and other forms of sepsis.27 If this is true, then the
use of a nonspecific inhibitor of NO synthase would
be as effective as an inhibitor specific to the induc-
ible isoform. In addition, the inhibition of the induc-
ible isotype could hinder immune defense and bac-
tericidal mechanisms that are important in sepsis.28
Furthermore, the detrimental effects described in
many of these studies may be explained by adminis-
tration of the inhibitor in the early phase of sepsis. In
this situation, the inducible NO synthase will not be
fully expressed since this takes a lag-phase of several
hours2 and only the constitutive NO synthase will be
blocked, resulting in severe and detrimental vaso-
constriction. In addition, the detrimental effects are
dose dependent and mostly seen in studies using
extremely high doses of the NO synthase inhibitor.29
In our study, patients received L-NAME, 1 mg/
kg/h, for 12 h, resulting in a total dose of 12 mg/kg of
L-NAME, which is relatively low compared with the
doses of NO inhibitors used in most animal stud-
ies12,13 and comparable to the doses used in studies
in humans.14-16,30 Animal studies have shown that
L-NAME is probably a prodrug that is converted to
the active L-NNA, which is much more stable
and has a high plasma half-life.31 However, little is
known about pharmacokinetics and metabolism of
L-NAME in humans. To minimize the potential
Figure 3. Effect of continuous infusion of 1 mg/kg/h of L-
NAME on plasma levels of nitrite and nitrate, the stable end-
products of NO metabolism, in patients with severe septic shock.
Time of L-NAME infusion is from t50 to t512 h. Values are
displayed as mean6SEM; for all values, p.0.05 compared with
the baseline value.
Table 3—Effect of L-NAME Infusion on Pulmonary and Metabolic Variables in Patients With Severe Sepsis*
Continuous L-NAME Infusion
Baseline 1 h 3 h 6 h 12 h 15 h 18 h
FIo2, % 5766 5766 5666 5165 5065 5165 5065
PaO2, mm Hg 81.065.4 99.4610.6
‡ 107.6613.5‡ 93.167.9‡ 84.867.5 81.564.6 77.664.8
PaCO2, mm Hg 34.961.3 35.561.3 36.261.4 35.561.1 35.461.4 34.761.5 36.161.5
P(A-a)O2, mm Hg 292648 273648 258642
‡ 234640‡ 236639‡ 246646 242646
PvO2, mm Hg
† 41.361.8 41.861.7 40.762.0 39.361.9 40.361.6 40.061.4 39.661.6
Qva/Qt, %† 19.462.6 17.162.9‡ 14.962.6‡ 14.262.1‡ 14.362.3‡ 14.162.2‡ 13.962.2‡
O2ER, %
† 21.162.4 23.362.7 24.762.6‡ 25.362.7‡ 24.162.1 24.462.5 23.562.1
Do2, mL/min/m
2† 713668 658664‡ 600651‡ 621655‡ 644660 673657 653649
V˙o2, mL/min/m
2† 158612 153613 151610 162612 156616 167619 159619
*P(A-a)O25alveolar arterial oxygen difference; PvO25partial pressure of venous oxygen; O2ER5oxygen extraction ratio. Values are displayed as
mean6SEM of 11 († or eight) patients.
‡p,0.05 for comparison to the baseline value.
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chance of developing toxic reactions from high se-
rum levels of L-NAME or L-NNA, we did not
continue L-NAME infusion for a longer period than
12 h and we did not restart L-NAME therapy when
patients redeveloped hypotension. At this time, we
do not know whether the optimum therapeutic dose
of L-NAME was used and possibly the 12-h admin-
istration period of L-NAME was too short for clinical
improvement. Further pharmacodynamic studies
will be necessary to find the optimum dose and
schedule for L-NAME administration.
Our findings show that L-NAME can raise BP in
patients with severe septic shock through preventing
excess vasodilatation. Similar results have been
found in previous studies using analogues of L-
arginine in human sepsis,14-16 although most reports
describe only initial effects. The hemodynamic ef-
fects of L-NAME were direct in onset and persisted
during the 12 h of infusion. However, the effect on
BP was most pronounced in the first hour of infusion
and tended back toward baseline after 1 h of L-
NAME infusion. Since SVR remained elevated, the
decline in BP was probably caused by a concomitant
decrease in CI and SV, although some form of
tolerance or counterregulation may have played a
role.
The reduction in CI has been reported with other
inhibitors of NO synthesis in both animals and
humans.12-16 So far, the precise mechanism underly-
ing this reduction in CO remains unclear. In our
study, it could partially have resulted from a reflex
change due to the increased SVR and afterload, or a
reduction in vasopressor support. Since LVSW was
improved during L-NAME infusion and heart rate
and RVSW were not significantly changed, direct
cardiac depression by L-NAME seems unlikely.
Myocardial depression secondary to myocardial ische-
mia32 could have played a role, although no changes
on the ECG were observed during L-NAME infu-
sion. The reduction in CI and concomitantly Do2
may be harmful since tissue perfusion may be re-
duced. Therefore, we included only patients with
hyperdynamic sepsis as characterized by increased
CI. The observations that V˙o2 was unaffected and
arterial lactate and pH were unchanged suggest that
L-NAME did not promote anaerobe metabolism and
that L-NAME preferentially caused vasoconstriction
in metabolic inactive tissues. However, these obser-
vations include only indirect parameters that do not
necessarily reflect what happens at capillary or cel-
lular level. Thus, despite these findings, local areas of
tissue underperfusion could have existed during
L-NAME infusion.
NO contributes to pulmonary vascular tone and
inhaled NO can be used to reduce pulmonary hy-
pertension and improve oxygenation in patients with
ARDS.19,33 That NO vasodilates the pulmonary vas-
culature is underscored by the finding that L-NAME
increased PAP and PVR. Pulmonary vasoconstriction
is an undesirable effect that may lead to pulmonary
hypertension and related deleterious effects on cir-
culation, particularly on right-sided cardiac function.
Indeed, in prior pilot experiments, we found that
higher doses of L-NAME resulted in severe pulmo-
nary hypertension. The pulmonary vasoconstriction
seen with L-NAME and other inhibitors of NO
synthase12-15 may limit their clinical application,
especially in patients with high PAP. Since NO
inhalation may improve oxygenation in patients with
ARDS, we hypothesized that inhibition of NO syn-
thesis might lead to problems in pulmonary gas
exchange. However, we found that arterial oxygen-
ation was improved during L-NAME infusion de-
spite pulmonary vasoconstriction. Parallel to this,
there was a reduction in Qva/Qt that implicates a
decrease of the pulmonary right-to-left shunt. This
may suggest that L-NAME caused a redistribution of
intrapulmonary blood to well-ventilated alveoli, im-
proving ventilation-perfusion mismatch. Similar ef-
fects of L-NAME on arterial oxygenation were de-
scribed by Sprague et al34 using a model of unilateral
alveolar hypoxia in anesthetized rabbits. Further-
more, in a study by Radermacher et al,35 it was found
that the increase in CO by systemic administration of
nitrovasodilators worsened ventilation-perfusion
mismatching and gas exchange in patients with
ARDS. The combined use of NO inhalation with
systemic inhibition of NO synthesis may prove to be
effective therapy in the future.36
Nine of 11 patients had increased levels of nitrite
and nitrate in the serum as compared with control
subjects. Although this could reflect increased sys-
temic NO production,6 some reservations must be
made, since NO is but one of the ways that nitrite
and nitrates are formed. L-NAME infusion did not
result in reduced serum levels of nitrite and nitrate,
despite profound vasoconstriction. At this time, we
cannot explain this finding, but it could suggest that
L-NAME is not an effective inhibitor of NO synthe-
sis and other mechanisms, independent of systemic
inhibition of NO synthesis, may play a role in the
increase in MAP and SVR by L-NAME.25 Further-
more, serum levels of nitrite and nitrate may not
directly reflect the local amount of NO released or
inhibited since active excretion through kidneys and
GI tract takes place.37
In conclusion, prolonged inhibition of NO synthe-
sis with L-NAME may improve cardiovascular status
with improvement of pulmonary gas exchange in
patients with severe septic shock. Mortality rate was
high, which could suggest only limited effects of
L-NAME on outcome. Furthermore, the increase in
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PAP and the reduction in CO are potentially harmful
effects that may hinder the clinical utility of L-
NAME and other NO synthase inhibitors. More
randomized clinical studies will be required to fur-
ther investigate whether inhibition of NO synthesis is
beneficial in human septic shock.
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